In 2019, The Eye Cancer Foundation’s Fellow, Dr. Ankit Tomar, successfully presented two research projects at medical conferences in San Francisco, USA. To eye cancer specialists and ophthalmic pathologists at the AAOOP and American Academy of Ophthalmology Annual Meetings, Dr Tomar presented on Ciliary Body Leiomyoma: Clinicopathologic Correlation in 3 Cases. In his series, Dr. Tomar shows how ciliary body leiomyomas can be indistinguishable from ciliary body melanoma. Only special pathology testing of tumor tissue samples are needed to separate these clinical dopplegangers.
Dr. Tomar also presented on Dr. Finger’s well-known innovation, the ophthalmic palladium-103 plaque brachytherapy. In this study, he explored the safety and tolerability of this method for patients with multifocal iris melanoma. This study was entitled Palladium-103 Plaque Therapy for Multifocal Iris Melanoma: Radiation of the Entire Anterior Segment. Drs. Finger and Tomar discovered this method was highly effective for this ocular cancer treatment since 1990! In this series, plaque radiation therapy achieved 100% local control and eye retention! This is remarkable because eyes with diffuse iris melanoma are commonly removed (enucleated).
The Eye Cancer Foundation is proud to support research that improves methods of diagnosis and treatment for eye cancer. Our fellows earn grants to present ECF research and learn about cutting edge technology and techniques. By spreading knowledge of ECF studies and findings, The Eye Cancer Foundation and its fellows like Dr. Ankit Tomar spread hope for those who would otherwise lose both sight and life.
Dr. Finger (left) and Dr. Tomar (right)
Dr. Tomar’s presentation poster on Ciliary Body Leiomyoma: Clinicopathologic Correlation in 3 Cases.
Dr. Tomar’s presentation poster on Palladium-103 Plaque Therapy for Multifocal Iris Melanoma: Radiation of the Entire Anterior Segment.
